

Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

October 5, 2016

CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.

Details of the presentation are as follows:

Jefferies Gene Editing/Therapy Summit

Date: Tuesday, October 11, 2016 Location: New York, New York

Times: Panel discussion at 10:00 am ET with company presentation to follow at 2:00 pm ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:

Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 jenn.smoter@intelliatx.com

Investor Contacts:

John Graziano Trout Group +1 646-378-2942 jgraziano@troutgroup.com

Chad Rubin
Trout Group
+1 646-378-2947
crubin@troutgroup.com



Intellia Therapeutics, Inc.